{"contentid": 488210, "importid": NaN, "name": "\"Back and forth\" on AstraZeneca vaccine adds to uncertainty", "introduction": "Germany has again updated its guidance on the use of Vaxzevria, after new reports related to a rare kind of blood clotting occurring in people who had previously received the vaccine.", "content": "<p><span style=\"font-weight: 400;\">Germany has again updated its guidance on the use of Vaxzevria, after new reports related to a rare kind of blood clotting occurring in people who had previously received the vaccine.</span></p>\n<p><span style=\"font-weight: 400;\">The product, developed by UK-based AstraZeneca (LSE: AZN) in conjunction with scientists from Oxford University, was previously known as COVID-19 Vaccine AstraZeneca.</span></p>\n<p><span style=\"font-weight: 400;\">The company has said a review of data from millions of vaccinations show there is no evidence of an association between blood clotting and the product.</span></p>\n<p><span style=\"font-weight: 400;\">This position has been backed by regulators, including the UK&rsquo;s Medicines and Healthcare Products Regulatory Agency (MHRA) and the European Medicines Agency, bas well as the World Health Organization, all of which have said the benefits continue to outweigh any possible risk.</span></p>\n<h2><strong>&ldquo;Back and forth&rdquo;</strong></h2>\n<p><span style=\"font-weight: 400;\">Countries across Europe previously </span><a href=\"https://www.thepharmaletter.com/article/ema-view-unchanged-on-astrazeneca-jab-despite-possible-link-to-blood-clots\"><span style=\"font-weight: 400;\">suspended their use</span></a><span style=\"font-weight: 400;\"> of the vaccine, in order to investigate a small number of cerebral sinus vein thrombosis (CSVT) cases.</span></p>\n<p><span style=\"font-weight: 400;\">Following the release of more encouraging safety data from the firm&rsquo;s USA-based Phase III trial, and a review from regulators, vaccination campaigns were allowed to recommence.</span></p>\n<p><span style=\"font-weight: 400;\">However, Canada, France and Germany have all now restricted its use to older people, in light of the fact that the risk of coronavirus applies to this demographic in particular, while cases of CSVT appeared to affect younger people.</span></p>\n<p><span style=\"font-weight: 400;\">This reverses the earlier position of countries like France and Germany, which previously said it should only be used in younger people and not the over 65s, after doubts over efficacy. These were subsequently allayed by fuller data from the firm's clinical trial program.</span></p>\n<p><span style=\"font-weight: 400;\">German lawmaker Markus Soeder objected to the \"back and forth\" around the vaccine, highlighting concerns that uncertainty from public health authorities could undermine confidence in the vaccine development process.</span></p>\n<p><span style=\"font-weight: 400;\">According to Germany&rsquo;s Paul Ehrlich Institute, there have been 31 cases of CSVT in the country among those who received the vaccine. It is unclear how many cases there have been among those who did not receive it.</span></p>", "date": "2021-03-31 11:41:00", "meta_title": NaN, "meta_keywords": "vaccine, previously, people, AstraZeneca, cases, blood, clotting, Germany, received, CSVT, related, rare, kind, reports, Vaxzevria, guidance, uncertainty", "meta_description": "Germany has again updated its guidance on the use of Vaxzevria, after new reports related to a rare kind of blood clotting occurring in people who had previousl", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-31 10:39:21", "updated": "2021-03-31 11:42:54", "access": NaN, "url": "https://www.thepharmaletter.com/article/back-and-forth-on-astrazeneca-vaccine-adds-to-uncertainty", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "germany_big.jpg", "image2id": "germany_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Infectious diseases, Vaccines", "topic_tag": "Coronavirus, Focus On, Public health, Regulation", "geography_tag": "Europe, Germany, UK", "company_tag": "AstraZeneca", "drug_tag": "COVID-19 Vaccine AstraZeneca, Vaxzevria", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-31 11:41:00"}